Saxenda

Short answer: yes — if you stop a GLP‑1 (semaglutide, tirzepatide, etc.) most people will regain at least some — often much — of the weight they lost unless they replace the drug’s effect with strong, sustained lifestyle and/or other medical interventions. Stopping doesn’t permanently “reset” appetite or metabolism for most people; the drug’s appetite‑suppressing and metabolic effects wear off and hunger, food reward, and energy balance often revert. What typically happens after stopping Appetite and cravings usually increase. GLP‑1 drugs reduce hunger and food reward; when they’re stopped those signals typically return. Weight regain is common and can begin within weeks to months; many studies and clinical experience show substantial regain over 6–12 months if no other measures are taken. If you are taking the GLP‑1 for diabetes, stopping can raise blood glucose; you’ll need closer monitoring and possible adjustments of other diabetes medicines. Side effects that occurred while taking the drug (nausea, constipation) generally improve after stopping. If you plan pregnancy, GLP‑1s are usually stopped because fetal safety isn’t established. Why regain happens GLP‑1 drugs treat physiology (appetite, satiety, gastric emptying) but not always the behavioral, environmental, or biological drivers that led to weight gain in the first place. Metabolic adaptations to weight loss (lower resting energy expenditure, stronger hunger signals) persist and are unmasked when the drug is stopped. How to reduce or slow regain (practical steps) Don’t stop abruptly without a plan. Talk with your prescribing clinician first. If you have diabetes, glucose monitoring is essential. Work with a team: primary care or endocrinologist + registered dietitian (RD) experienced in weight management. RDs can teach meal plans, protein/fiber strategies, and appetite management. Nutrition & exercise: prioritize higher protein, fiber, and regular resistance training to preserve lean mass and resting metabolism. Aim for consistent meals and reduce liquid calories. Behavioral strategies: structured programs, cognitive behavioral therapy (CBT) for eating, and regular self‑monitoring (weight, food logs) help maintain loss. Consider pharmacologic maintenance: some people switch to or continue a lower‑dose GLP‑1 as maintenance or use another FDA‑approved obesity med (see options below). Discuss risks, benefits, and cost with your clinician. Regular follow‑up and early action if weight starts to creep back up (more intensive diet/physical activity or re‑starting meds) give the best chance to maintain loss. Medications and services you can discuss with your clinician GLP‑1s: Wegovy and Ozempic (semaglutide), Zepbound or Mounjaro (tirzepatide). These are effective for weight but most benefit is while you stay on them. Other FDA‑approved options for weight management: Saxenda (liraglutide), Qsymia (phentermine/topiramate), Contrave (bupropion/naltrexone), and orlistat (Xenical/Alli). These have different side effects and efficacy — your doctor can advise which might suit you. Behavioral programs: WW (Weight Watchers) or the CDC Diabetes Prevention Program (DPP) for structured lifestyle support. These provide regular coaching and accountability. Digital tools: Noom (behavioral/psychology focus), MyFitnessPal or Cronometer (tracking calories and protein). These help with self‑monitoring, which predicts better maintenance. Professional support: find a board‑certified obesity medicine specialist or endocrinologist, and a registered dietitian (look for “RD” or “RDN”). Many clinics offer multidisciplinary weight‑management programs. Questions to ask your clinician before stopping What will happen to my blood sugar/medications if I stop? Can we create a maintenance plan (diet, exercise, follow‑up schedule) before I stop? Are there alternative medications or a taper/transition strategy appropriate for me? What monitoring (weight, labs) should we do and how often? Bottom line Stopping a GLP‑1 commonly leads to increased appetite and weight regain unless you have a concrete, evidence‑based maintenance plan (behavioral program, diet/exercise, and/or alternative medication). Talk with your prescriber and a dietitian to create a personalized plan before you stop so you can maximize the chance of keeping your losses. If you want, tell me which medication you’re on and why you’re stopping (cost, side effects, pregnancy, etc.), and I can suggest a more specific transition plan and questions to take to your clinician.

Mentioned in position 5 of 13

Weight Loss on GLP-1 Medications Typical Results Most people lose 1-2 lbs per week in the early months Total loss over 12-18 months averages: Ozempic/Wegovy (semaglutide): ~15-20% of body weight Mounjaro/Zepbound (tirzepatide): ~20-25% of body weight (currently the strongest option) Victoza/Saxenda (liraglutide): ~5-8% (older, less effective) Sustainability - The Honest Answer The tricky part: Most people regain significant weight if they stop the medication. Studies show ~2/3 of lost weight returns within a year of stopping. For sustainable results, consider: Noom Med or Calibrate - combine medication with coaching/lifestyle programs Found or Ro Body - telehealth platforms with behavioral support built in Working with an obesity medicine specialist rather than just a primary care doctor What Actually Helps Long-Term Building muscle through strength training while losing Developing eating habits that work with the medication Having a plan for maintenance dosing or tapering Bottom Line Think of it more like a chronic medication than a quick fix - similar to blood pressure treatment. The results can be dramatic, but the lifestyle work alongside it determines how lasting they are. Want recommendations on how to access these medications?

Mentioned in position 4 of 8

Short answer: usually no — compounded GLP‑1s are rarely the best first option. They can be cheaper or easier to get, but they carry real safety, quality and legal risks and lack the FDA-approved manufacturing and testing that Wegovy (semaglutide 2.4 mg) has. There are safer, often better paths to pursue first. What to consider and practical next steps 1) Appeal the denial first Ask your prescriber to submit a formal prior‑authorization appeal or peer‑to‑peer review with the insurer and to write a letter of medical necessity documenting your BMI, weight‑related conditions, prior therapies tried, and why Wegovy is clinically indicated. Denials are often reversed on appeal. If you want, I can help draft a short appeal/medical‑necessity paragraph you can give your clinician. 2) Check manufacturer and savings programs Novo Nordisk offers patient support and savings programs for Wegovy. If you have commercial insurance, co‑pay savings or patient support may reduce cost; for Medicare recipients, manufacturer coupons usually aren’t allowed, but patient assistance programs may still help. Contact Novo Nordisk Patient Support for details. 3) Consider alternative, FDA‑approved options (safer than compounding) Zepbound (tirzepatide, Eli Lilly) — FDA‑approved for chronic weight management; may be covered differently by insurers and is very effective for weight loss. Mounjaro (tirzepatide, Lilly) — approved for type 2 diabetes but commonly used off‑label for weight loss; discuss this with your clinician. Ozempic (semaglutide, Novo Nordisk) — approved for diabetes; some clinicians use it off‑label at higher doses for weight management. Saxenda (liraglutide, Novo Nordisk) — older daily injectable weight‑loss drug, FDA‑approved for obesity. These have established safety data and manufacturer quality controls; your prescriber can try switching or request coverage for one of these. 4) Clinical trials and programs Look for clinical trials of GLP‑1 or tirzepatide products (ClinicalTrials.gov) — some trials provide medication at no cost. 5) If you’re thinking about compounded GLP‑1s — major cautions Compounded GLP‑1s are not FDA‑approved products. Quality (potency, purity) and sterility can vary. There have been reports of contamination, incorrect dosing, and supply of unauthorized ingredients. Insurance typically won’t cover compounded versions. If you still consider compounding, only use a reputable, accredited compounding pharmacy (look for PCAB accreditation and documented sterility/potency testing). Ask the pharmacy for their certificate of analysis, sterility testing procedures, lot records, and how the active pharmaceutical ingredient is sourced. Be extremely cautious about mail‑order or overseas sources, and avoid “too good to be true” prices. 6) Other options to discuss with your clinician Intensified lifestyle program, referral to a registered dietitian or behavioral program. Bariatric surgery evaluation if you meet criteria. Older, non-GLP‑1 medicines for weight management (Contrave, Qsymia) if appropriate. Summary recommendation Don’t jump to compounded GLP‑1s as the first fix. First: appeal the denial, check Novo Nordisk’s support programs, and ask your clinician about covered FDA‑approved alternatives such as Zepbound, Mounjaro, Ozempic, or Saxenda. Reserve compounding only as a last‑resort after careful vetting of a PCAB‑accredited pharmacy and full informed discussion about risks. If you want, tell me: Your insurance type (commercial, Medicare, Medicaid), BMI and any weight‑related conditions, and whether your clinician has tried an appeal — and I can help draft an appeal letter or suggest the most promising alternative based on your situation.

Mentioned in position 5 of 7

This is a fantastic and very timely question, as the world of GLP-1 medications can be complex, especially with the rise of compounding pharmacies. Let's break down the difference between FDA-approved GLP-1s (injectable and oral) and compounded oral versions. The Short Answer: FDA-approved oral GLP-1s (like Rybelsus) do work, but they have specific absorption mechanisms and tend to be less potent for weight loss than the injectable versions. Compounded GLP-1 drops or tablets are generally NOT considered reliable or effective, and carry significant safety concerns. Why FDA-Approved Oral GLP-1s Work (and How They Differ) There is currently one FDA-approved oral GLP-1 medication on the market: Rybelsus (semaglutide): This is the oral form of the same active ingredient found in Ozempic and Wegovy. It works because it's formulated with a special absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]). SNAC protects the semaglutide from being broken down by stomach acid and helps it get absorbed into the bloodstream. Key differences and considerations for Rybelsus: Absorption Requirements: It must be taken on an empty stomach with a very small amount of plain water (no more than 4 ounces), and you must wait at least 30 minutes before eating, drinking, or taking any other medications. This strict regimen is crucial for its effectiveness. Bioavailability: Even with SNAC, the bioavailability (how much of the drug actually enters circulation) of oral semaglutide is much lower than the injectable form. This means you need a much higher dose orally to achieve a similar effect to an injectable dose. Efficacy: While effective for blood sugar control in type 2 diabetes, its weight loss efficacy is generally considered less robust than the injectable Wegovy (which is semaglutide at higher, weight-loss specific doses) or Zepbound*. Why Compounded GLP-1 Drops or Tablets Are Problematic When people refer to "compounded GLP-1 drops or tablets," they are usually talking about products made by compounding pharmacies that claim to contain semaglutide or tirzepatide in an oral form, often without the specific SNAC technology found in Rybelsus. Here's why these are generally not recommended: Poor Absorption (The Biggest Issue): GLP-1s are large peptide molecules. They are extremely fragile and are rapidly destroyed by stomach acid and digestive enzymes. Without a specialized absorption enhancer like SNAC, taking a GLP-1 as a regular pill or drop orally will result in minimal to virtually no absorption into your bloodstream. Your body will simply break it down before it can have any therapeutic effect. Lack of FDA Oversight: Compounded medications are not reviewed or approved by the FDA for safety, efficacy, or quality. This means: Purity & Potency Concerns: There's no guarantee that the product contains the stated amount of the active ingredient, or that it's free from contaminants. The active ingredient itself might not be pharmaceutical grade. Active Ingredient Form: Compounded products often use "salts" of semaglutide (e.g., semaglutide sodium) which are not the same as the active ingredient in FDA-approved medications and have not been proven safe or effective. Unproven Efficacy: Because of the absorption issues and lack of quality control, compounded oral GLP-1s have no reliable evidence to suggest they work for weight loss or blood sugar control. Any reported effects are likely due to a placebo effect or other factors. Safety Risks: Without FDA oversight, you could be taking a product that is ineffective, contains harmful impurities, or has inconsistent dosing, leading to unpredictable side effects or lack of desired therapeutic effect. Injections (The Gold Standard for Potency and Reliability) FDA-approved injectable GLP-1s are considered the most effective and reliable form of these medications: Semaglutide: Ozempic: For type 2 diabetes, often used off-label for weight loss. Wegovy: Specifically approved for chronic weight management. Tirzepatide: Mounjaro: For type 2 diabetes, often used off-label for weight loss. Zepbound: Specifically approved for chronic weight management. Liraglutide: Victoza: For type 2 diabetes. Saxenda: Specifically approved for chronic weight management. Why they work so well: Injecting the medication bypasses the digestive system entirely, ensuring high bioavailability and consistent delivery of the active ingredient directly into your bloodstream. This allows for precise dosing and predictable effects, backed by extensive clinical trials. Recommendation: Given the significant concerns with compounded oral GLP-1s, here's what is generally recommended: Prioritize FDA-Approved Medications: If you're considering a GLP-1 medication, discuss FDA-approved options with your doctor. These include: Injectables: Wegovy or Zepbound for weight loss, or Ozempic, Mounjaro, or Saxenda if you have type 2 diabetes or meet specific criteria for off-label use. Oral: Rybelsus if an injectable is not feasible or desired, and you are comfortable with its specific administration requirements and potentially lower weight loss efficacy. Avoid Compounded Oral Versions: Due to the lack of evidence for efficacy and serious safety concerns, it's strongly advised to avoid compounded GLP-1 drops or tablets. Consult Your Doctor: Always have an open and honest conversation with a qualified healthcare provider. They can assess your individual health needs, discuss the risks and benefits of all available options, and help you determine the safest and most effective treatment plan. While the convenience of an oral compounded medication might seem appealing, the scientific realities of GLP-1 absorption and the lack of regulatory oversight make them a risky choice. Stick to proven, FDA-approved options for your safety and health.

Mentioned in position 5 of 5

It's completely understandable to feel frustrated when your insurance denies a medication like Wegovy, especially when you know it could be beneficial. While compounded GLP-1s might seem like a more accessible and affordable option, it's crucial to understand their pros and cons and explore all alternatives. Are Compounded GLP-1s Your Best Option? Not necessarily, and they come with significant caveats. Compounded medications are custom-made by a pharmacy for an individual patient based on a doctor's prescription. They are generally only intended for situations where an FDA-approved drug is unavailable, or a patient has specific needs (like an allergy to an inactive ingredient in the brand-name version). Here's a breakdown: Potential Downsides and Risks of Compounded GLP-1s: Not FDA-Approved: This is the biggest concern. Compounded drugs do not undergo the rigorous safety and efficacy testing that the FDA requires for brand-name medications like Wegovy. This means their quality, potency, and purity are not guaranteed. Safety Concerns: The FDA has issued strong warnings against compounded semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Zepbound and Mounjaro) due to reports of adverse events. Some compounded versions might use salt forms of the active ingredient, which are not the same as the active ingredients in the FDA-approved drugs. Lack of Oversight: There's less regulatory oversight for compounding pharmacies compared to pharmaceutical manufacturers. This can lead to variations in the quality of ingredients, manufacturing processes, and sterile conditions. Uncertain Efficacy: Since they haven't been through clinical trials, there's no guarantee that a compounded GLP-1 will work as effectively or predictably as the brand-name version. Legality/Availability: The ability to compound these drugs depends on the original FDA-approved drug being on the FDA's "drug shortage" list. When the shortage eases, compounding may become illegal. Why People Consider Compounded GLP-1s: Cost: They are often significantly cheaper than the brand-name versions, especially without insurance coverage. Accessibility: They offer an alternative when brand-name drugs are in short supply or denied by insurance. Before considering a compounded GLP-1, I strongly recommend exploring these other options: Appeal Your Insurance Denial: This is often the best first step. Work with your doctor to submit an appeal, providing medical documentation of your need for Wegovy, previous weight loss attempts, and any co-existing conditions. Sometimes, a detailed letter from your physician can make a difference. Explore Other FDA-Approved GLP-1 Medications for Weight Management: Zepbound (tirzepatide): This is the newest FDA-approved GLP-1 (and GIP) receptor agonist specifically for chronic weight management. It's often very effective, and your insurance might cover it even if they denied Wegovy. Saxenda (liraglutide): This is an older, daily injectable GLP-1 specifically approved for weight management. While it might be slightly less potent than Wegovy or Zepbound, it's a proven option. Ozempic (semaglutide for Type 2 Diabetes) or Mounjaro (tirzepatide for Type 2 Diabetes): While these are approved for Type 2 Diabetes, they are the same active ingredients as Wegovy and Zepbound. If you have Type 2 Diabetes, your insurance might cover them, and weight loss is a significant side effect. However, using them off-label solely for weight loss can be challenging for insurance coverage.* Explore Other FDA-Approved Weight Loss Medications (Non-GLP-1s): Contrave (bupropion/naltrexone): An oral medication that works on brain pathways to reduce appetite and cravings. Qsymia (phentermine/topiramate extended-release): An oral combination medication that suppresses appetite and increases feelings of fullness. Xenical (orlistat) / Alli (over-the-counter orlistat): Works by blocking the absorption of some fat in your diet. Phentermine: A stimulant used short-term (typically up to 12 weeks) for appetite suppression. Consider Bariatric Surgery: If you meet the criteria (BMI usually 35+ with co-morbidities or 40+ without), bariatric surgery is a highly effective, long-term weight loss solution often covered by insurance. Work with a Medical Weight Loss Specialist: A doctor specializing in obesity medicine can help you navigate insurance appeals, explore all FDA-approved options, and create a comprehensive plan that includes diet, exercise, and behavioral therapy. If you absolutely must consider a compounded GLP-1 (after exhausting all other options and in discussion with your doctor): Only obtain it from a licensed, reputable compounding pharmacy with a valid prescription from your doctor. Ask detailed questions about their sourcing of ingredients, quality control, and testing procedures. Avoid "med spas" or online pharmacies that offer these without proper medical consultation and oversight. Be fully aware of the risks and monitor for any unusual side effects. In summary, while compounded GLP-1s exist, they are generally not your "best option" due to significant safety and quality concerns. Your primary focus should be on appealing your insurance denial for Wegovy or exploring other FDA-approved medications like Zepbound or Saxenda with your doctor. Always consult with your healthcare provider to discuss the best and safest course of action for your individual health needs.

Mentioned in position 5 of 9

Short answer: usually no — compounded GLP‑1s are not the best first option for most people. Try appeal routes, manufacturer help, or FDA‑approved alternatives before using compounded products. If you’re still considering compounding, only do so after careful checks (see below). Why compounded GLP‑1s are risky Not FDA approved: potency, purity, sterility and stability aren’t guaranteed the way brand drugs are. Infection/contamination risk with injectable compounding (there have been serious outbreaks in the past). Insurance almost never covers compounded versions — you’ll likely pay out of pocket. Limited liability/support: no manufacturer safety program or established pharmacovigilance. What to try first (recommended actions) Appeal the denial Ask your prescriber to submit a prior‑authorization appeal or a peer‑to‑peer review. Provide clinical documentation (BMI, comorbidities, prior weight‑loss attempts, labs). Appeals are often successful. Check manufacturer assistance and copay programs Novo Nordisk (Wegovy) and Eli Lilly (Zepbound/Mounjaro) offer patient support, co‑pay savings or patient assistance programs that can substantially lower cost for eligible patients. Contact the company’s patient support line or your prescriber’s office to enroll. Ask about other FDA‑approved options Saxenda (liraglutide) — FDA‑approved for weight management (different dosing but established safety record). Zepbound (tirzepatide) and Mounjaro (tirzepatide) — tirzepatide is available from Eli Lilly; Zepbound is approved for chronic weight management (discuss availability/cost with prescriber). Ozempic (semaglutide) or Rybelsus (oral semaglutide) — approved for diabetes but sometimes used under clinician guidance; insurance coverage may differ. Non-GLP‑1 weight medications: Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion), Xenical/Alli (orlistat) — these may be better covered by insurance. Your clinician can recommend which alternative fits your medical profile. Look for lower legitimate prices Use price‑comparison/coupon services such as GoodRx to check retail savings. Specialty pharmacies (CVS Specialty, Accredo, Optum Specialty) may be able to help with access and prior‑auth navigation. Consider clinical trials Search clinicaltrials.gov for trials of GLP‑1 or tirzepatide weight‑loss studies — participants may receive medication at no cost. If you’re considering compounded GLP‑1s (only after exhausting other options) Only use a reputable, licensed compounding pharmacy that follows sterile USP <797> standards. Ask for: Evidence of state board licensure and sterile compounding certification. Certificate of analysis, lot testing, and expiration/stability data. Written info on sterility testing and storage/handling. Discuss risks with your prescriber and get written informed consent. Understand your insurer almost certainly won’t cover it. If you’d like, I can: Help draft an appeal/prior‑authorization letter your clinician can use (I can include the clinical points insurers typically want). Look up patient assistance/savings program phone numbers and links for Wegovy or Zepbound (tell me your country). Walk through what to ask a compounding pharmacy if you end up considering that route. Tell me which country you’re in and why Wegovy was denied (medical reason on the denial) and I’ll tailor the next steps.

Mentioned in position 3 of 15